Fever. Cough. Sore throat. Fatigue. Breathing difficulties.
These symptoms can immediately suggest a respiratory infection, but they do not necessarily tell a clinician which respiratory virus is responsible.
Influenza A, Influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2 can produce overlapping symptoms. So this presents a very familiar challenge for clinicians and laboratories: as clinical presentation alone may not provide enough information to reliably identify the pathogen causing a respiratory illness.
For healthcare facilities with molecular diagnostic capability, multiplex respiratory PCR testing provides one approach: testing a patient sample for several respiratory pathogens simultaneously rather than performing a separate molecular test for each suspected virus.
The Bosch Vivalytic SARS-CoV-2 DT, Flu A/B, RSV test uses qualitative real-time PCR to detect four respiratory viral targets from a single test, with results available in approximately 60 minutes.
Why Respiratory Symptoms Alone May Not Identify the Pathogen
Respiratory viruses frequently share clinical features.
- Influenza, for example, commonly causes fever, cough, headache, muscle and joint pain, malaise and sore throat.
- RSV can similarly cause respiratory symptoms ranging from relatively mild illness to severe lower respiratory disease.
- SARS-CoV-2 adds another potential cause of overlapping respiratory symptoms.
So the result is a diagnostic problem:
A patient may clearly have an acute respiratory infection, but which virus is causing it?
That matters because the viruses differ in epidemiology, populations at risk, prevention strategies and approaches to patient management.
Bosch makes this same point in its Vivalytic respiratory test information, noting that SARS-CoV-2, Influenza A/B and RSV can produce overlapping symptoms while approaches to patient management can differ.
What Is Multiplex Respiratory PCR Testing?

PCR (polymerase chain reaction) is a molecular diagnostic technique used to detect specific genetic material associated with a pathogen.
A multiplex PCR assay is designed to investigate several targets within the same testing process.
So instead of asking only:
“Does this sample contain Influenza A?”
a multiplex respiratory assay can potentially ask several questions simultaneously:
Is Influenza A present?
Is Influenza B present?
Is RSV present?
Is SARS-CoV-2 present?
This approach can be particularly useful when different pathogens produce similar symptoms.
Why Is RSV Important?
Respiratory syncytial virus is another major cause of respiratory disease.
RSV is particularly important among infants and young children, although older adults and people with underlying health conditions can also develop severe disease.
WHO estimates that RSV causes more than 3.6 million hospitalisations and approximately 100,000 deaths among children under five each year. Importantly for the African context, WHO estimates that 97% of paediatric RSV deaths occur in low- and middle-income countries.
Yet RSV can be under-recognised as a cause of severe respiratory disease in lower-income settings.
This has prompted WHO to expand RSV surveillance using infrastructure developed through its Global Influenza Surveillance and Response System. Current work is particularly focused on improving disease-burden evidence among young children in low- and lower-middle-income countries.
For African healthcare systems, strengthening respiratory diagnostic capacity therefore has value beyond individual patient testing.
Laboratory data can also contribute to understanding which respiratory viruses are circulating, when they are circulating and which patient populations are being affected.
Why Test for Several Respiratory Viruses at the Same Time?

Imagine a patient presenting to a healthcare facility with fever, cough, fatigue and other respiratory symptoms.
Based solely on those symptoms, several respiratory pathogens may be plausible.
Testing only for one pathogen can answer one question.
A multiplex assay can investigate several possibilities simultaneously.
This has several potential practical advantages.
1. Similar symptoms can have different causes
Influenza, RSV and SARS-CoV-2 can produce overlapping clinical presentations.
Laboratory detection can therefore provide information that symptoms alone cannot reliably establish.
2. One sample can investigate several targets
Instead of performing individual molecular tests sequentially, a multiplex assay can test multiple pathogen targets within a single workflow.
3. Earlier differentiation may support patient management
Identifying the pathogen can provide clinicians with additional information when determining appropriate patient management, alongside clinical assessment and applicable guidelines.
4. Laboratories can make better use of molecular diagnostic capacity
A respiratory testing platform capable of investigating several common viruses can potentially be more useful than one dedicated to a single pathogen.
This becomes particularly relevant when healthcare organisations are evaluating the utilisation and economics of molecular diagnostic equipment.
How Does the Vivalytic Flu A/B, RSV and SARS-CoV-2 Test Work?

The Vivalytic combination test detects and differentiates nucleic acids associated with:
- SARS-CoV-2
- Influenza A
- Influenza B
- Human Respiratory Syncytial Virus (RSV)
The Bosch portfolio identifies specific genetic targets for each virus: the SARS-CoV-2 E-gene, Influenza A M-gene, Influenza B NP-gene and RSV F-gene.
The assay uses qualitative real-time PCR.
| Specification | Vivalytic SARS-CoV-2 DT, Flu A/B, RSV |
|---|---|
| Detectable Pathogens | SARS-CoV-2 (E-gene); Influenza A (M-gene); Influenza B (NP-gene); Human RSV (F-gene) |
| Detection Method | Qualitative real-time PCR |
| Sample Material | Nasopharyngeal swabs; oropharyngeal swabs; lolly-saliva swabs |
| Time-to-Result | Approx. 60 minutes |
| Field of Application | Symptomatic patients |
| Intended Setting | Professional and laboratory use; Near Patient Testing |
| Sample Volume | 300 μL per test |
| Compatible Transport Media | eNAT®; UTM® Universal Transport Medium™; Puritan™ UniTranz-RT Transport System; SIGMA VIROCULT® |
The complete specifications are provided in the Vivalytic portfolio brochure.
Healthcare professionals can also review the official Bosch Vivalytic SARS-CoV-2, Flu A/B and RSV test information.
What Happens Inside the Vivalytic Analyser?
An important consideration for laboratories is that molecular testing involves considerably more than simply placing a sample into a PCR machine.
- Sample preparation,
- nucleic-acid extraction,
- amplification and
- detection all form part of the molecular workflow.
Bosch states that the Vivalytic analyser automates these processes.
Its respiratory test workflow incorporates sample preparation, cell lysis, nucleic-acid extraction, PCR amplification and bio-analytical detection within the system.
The Vivalytic brochure consequently describes the respiratory assay as requiring no additional laboratory equipment, with only a few steps from sample to result.
For a laboratory evaluating molecular diagnostic capacity, this can be as important as the headline turnaround time.
The relevant question isn’t simply:
“How quickly does the PCR run?”
It is:
“What does the complete sample-to-result workflow require from our laboratory?”
What Could an Approximately 60-Minute Result Mean in Practice?
A one-hour result should not automatically be interpreted as guaranteeing a one-hour clinical decision.
Sample collection, patient flow, laboratory workload, reporting procedures and clinical interpretation all influence the real-world turnaround time.
- Nevertheless, the Vivalytic assay’s approximately 60-minute analytical workflow potentially allows information about four important respiratory viral targets to become available relatively quickly.
Consider a healthcare facility where respiratory samples would otherwise need to be transported to an external molecular laboratory.
The relevant comparison may not be:
60-minute PCR versus another 90-minute PCR.
It may instead be:
near-patient molecular testing versus sample transport, laboratory processing and subsequent result reporting.
This is why healthcare organisations should evaluate diagnostic equipment according to their existing patient and laboratory pathway, rather than turnaround time alone.
Is Multiplex PCR Appropriate for Every Respiratory Patient?
Not necessarily.
The availability of a multiplex test does not mean that every patient presenting with a cough or fever requires molecular testing for four viruses.
Testing decisions should follow applicable clinical guidelines, local epidemiology, patient characteristics and the healthcare organisation’s diagnostic protocols.
Laboratories must also consider economics.
A healthcare facility should understand:
- expected respiratory testing volumes;
- which patients are likely to be tested;
- whether samples are currently processed internally or externally;
- current turnaround times;
- cartridge and consumable costs;
- staffing requirements;
- local respiratory-virus circulation;
- and how the result would influence clinical management.
This is particularly important in settings where healthcare resources need to be carefully prioritised.
One Respiratory Cartridge, but a Much Broader Platform

The commercial significance of this test becomes clearer when considered alongside the wider Vivalytic portfolio.
The analyser is not restricted to respiratory testing.
Bosch’s current portfolio includes assays covering respiratory infections, gastrointestinal infections, sexually transmitted infections, nosocomial infections and bacterial meningitis.
This includes the MRSA/SA, Candida auris and Bacterial Meningitis tests discussed elsewhere in our MediDiagAfrica diagnostic blog series. Kindly click the above links if you’d love to learn more.
Questions Laboratory Managers Should Consider
Before introducing multiplex respiratory PCR testing, laboratory and healthcare decision-makers should consider:
- Which respiratory viruses do we currently test for?
- What are our average monthly and peak testing volumes?
- Do respiratory samples currently leave the facility for molecular testing?
- What is our real-world sample-to-result turnaround time?
- Would distinguishing Influenza A/B, RSV and SARS-CoV-2 within one assay provide useful clinical information?
- Which patient groups would be tested?
- How does respiratory-virus seasonality behave in our country or region?
- Do we currently have PCR infrastructure?
- What training would our staff require?
- How reliably can cartridges and consumables be supplied?
- What technical and after-sales support is available?
- Which additional Vivalytic assays could our facility potentially use?
These questions help move an equipment evaluation away from specifications alone and towards the actual diagnostic needs of the healthcare facility.
Is Your Laboratory Considering Multiplex Respiratory PCR Testing?
If your laboratory, hospital, clinic or healthcare organisation is reviewing its respiratory testing or wider molecular diagnostic capabilities, MediDiagAfrica can provide further information about the Bosch Vivalytic platform and the Vivalytic SARS-CoV-2 DT, Flu A/B and RSV assay.
The discussion can begin with your existing diagnostic requirements:
Which respiratory pathogens do you currently test for?
How quickly do you receive results?
Are samples processed locally or referred elsewhere?
Could the same molecular platform support other diagnostic requirements within your facility?
From there, you can:
Request information about the Vivalytic respiratory multiplex test
Request a Vivalytic demonstration
Discuss your laboratory’s molecular diagnostic requirements
Enquire about Vivalytic availability in your country
Bosch notes that not every Vivalytic product is available in every region, so availability should be confirmed for the individual market.
This article is intended for healthcare and laboratory professionals and provides general diagnostic and product information. It should not replace clinical guidelines, professional medical judgement, local diagnostic protocols or applicable regulatory requirements.
